Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region
Journal of International Medical Research, Volume 39, No. 2, Year 2011
Notification
URL copied to clipboard!
Description
The prevalence of painful diabetic peripheral neuropathy (DPN) was evaluated in type 1 or type 2 diabetes mellitus patients (n = 4097) attending outpatient clinics across the Middle East. Overall, 53.7% of 3989 patients with DN4 data met the criteria for painful DPN (Douleur Neuropathique-4 [DN4] scores ≥ 4). Significant predictors of painful DPN included long history (≥ 10 years) of diabetes (odds ratio [OR] 2.43), age ≥ 65 years (OR 2.13), age 50 - 64 years (OR 1.75), presence of type 1 versus type 2 diabetes (OR 1.59), body mass index ≥ 30 kg/m2 (OR 1.35) and female gender (OR 1.27). Living in one of the Gulf States was associated with the lowest odds of having painful DPN (OR 0.44). The odds of painful DPN were highest among patients with peripheral vascular disease (OR 4.98), diabetic retinopathy (OR 3.90) and diabetic nephropathy (OR 3.23). Because of the high prevalence and associated suffering, disability and economic burden of painful DPN, it is important that diabetic patients are periodically screened, using a simple instrument such as the DN4, and receive appropriate treatment if symptoms develop. © 2011 Field House Publishing LLP.
Authors & Co-Authors
Jambart, Sélim
Lebanon, Beirut
Hôtel-dieu de France Hospital
Ammache, Z.
Lebanon, Beirut
Clemenceau Medical Center
Haddad, F.
Jordan, Amman
King Hussein Medical Center, Amman
Younes, A.
Jordan, Amman
Private Practice
Hassoun, Ahmed A.K.
United Arab Emirates, Dubai
Dubai Diabetes Center
Abdalla, K.
Egypt, Alexandria
Faculty of Medicine
Abou Selwan, C.
United States, New York
Pfizer Inc.
Sunna, N.
United States, New York
Pfizer Inc.
Wajsbrot, Dalia Ballas
United States, New York
Pfizer Inc.
Youseif, E.
United States, New York
Pfizer Inc.
Statistics
Citations: 104
Authors: 10
Affiliations: 7
Identifiers
Doi:
10.1177/147323001103900204
ISSN:
03000605
Research Areas
Disability
Noncommunicable Diseases
Study Design
Cross Sectional Study
Case-Control Study
Participants Gender
Female